

## March 1, 2024 | Issue 311

## Editor's note

This note is produced every Friday by <u>KPMG</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list here</u>.

We welcome your feedback. Let us know if KPMG can help. Please reply to this email with any comments or requests.

> Subscribe here



## Healthcare regulatory news

President Biden <u>announced an Executive Order</u> to enhance US patients' data security; the order authorizes the Attorney General to prevent large-scale transfer of US healthcare data to countries of concern.

CMS released <u>final Part 1 guidance</u> on the Medicare Prescription Payment Plan established by the Inflation Reduction Act, providing key details to Part D plans about administering the monthly installment program.

The FDA <u>withdrew its approval</u> for multiple myeloma treatment Pepaxto due to clinical benefit and safety concerns; the withdrawal is the agency's first use of its power to rescind previously accelerated approvals... The FDA <u>approved</u> Xolair, the first treatment to reduce severe food-related allergic reactions after accidental exposure; Xolair was first approved in 2003 as an asthma treatment.





## Healthcare law and policy news

Congress is considering a less comprehensive health package that excludes proposed Pharmacy Benefit Manager (PBM) reforms, price transparency legislation, and other health provisions after failing to reach agreement on key spending priorities.

The DOJ <u>initiated an antitrust investigation</u> into UnitedHealth and its subsidiary Optum Health for potentially anti-competitive activity.... A DOJ <u>report</u> found False Claims Act settlements resulted in a record high \$2.7B in 2023, a 54% increase from 2022.

A federal judge approved a \$385M antitrust settlement between opioid manufacturer Indivior Inc. and drug wholesalers who claimed the manufacturer illegally suppressed generic competition for its treatment Suboxone... Sandoz agreed to a settlement in a PA pricing antitrust suit for \$265M.

Adventist Health to <u>acquire two CA-based hospitals</u> (\$550M) from Tenet Healthcare... Northwell Health and Nuvance Health <u>are merging</u> to form a 28-hospital health system in NY/CT.

A Reuters <u>analysis</u> found average US drug prices increased 35% from 2022-2023, citing the development of high-cost rare disease drugs and associated regulatory incentives such as market exclusivity, fee waivers, and tax credits as primary drivers.

Every Cure, a drug repurposing research non-profit <u>was awarded \$48M</u> by the Advanced Research Projects Agency for Health (ARPA-H) to develop an Al-powered drug repurposing database.

A CMS report on national quality measures found significant worsening in patient safety measures and persistent health equity gaps for historically disadvantaged populations during COVID-19; performance on 38% and 47% of quality measures were worse than expected in 2020 and 2021, respectively.





Questions or comments, please send to <u>us-hclspractice@kpmg.com</u>.

kpmg.com/socialmedia











Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2024 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. USCS011380-1B

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.